Abiopharma

Castle Biosciences to Participate in Upcoming Investor Conferences

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025

Alkermes plc Reports Third Quarter 2025 Financial Results

Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025

Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity

Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch

Tenet Reports Strong Third Quarter 2025 Results; Raises 2025 Financial Outlook

Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy

RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders

Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma